Endometrial cancer Flashcards
Endometrial cancer incidence
4th most common cancer in females
most common gynecological cancer
5 year survival ~70%
Oncogenesis of endometrial cancer
unopposed estrogen leading to hyperplasia, then ca
Natural history of endometrial cancer
extension through uterus
spread into lymph nodes and blood
Risk factors of endometrial cancer
unopposed estrogen (exogenous hormones, obesity, anovulation) obesity: 3-10x Lynch syndrome (lifetime risk 40-60%) HTN diabetes: 2-3x irregular menstruation nulliparity
Prevention of endometrial cancer
decrease BMI
Pre-cancerous stage of endometrial cancer
endometrial hyperplasia
Spread of endometrial cancer
Local: uterus, cervix, colon, bladder
Lymph: para-aortic nodes or pelvic nodes
Blood: uncommon, metastasis to lungs, liver, bone
SSx of endometrial cancer
Postmenopausal bleeding
abnormal vaginal bleeding
Diagnosis of endometrial cancer
biopsy
D&C if biopsy not enough
US can give suspicion but not diagnosis
Use IHC for all endometrial ca to screen for Lynch syndrome
Staging of endometrial cancer
surgical
I: confined to uterus (majority of patients present here)
II: cervix
III: adnexae
IV: bowel, bladder, distant metastasis (rare)
Tx of endometrial cancer
1) Surgery!
Hysterectomy + bilateral salpingo-oophorectomy +/- lymmphadenectomy
Adjuvant:
depending on stage and risk of recurrence
Pelvic radiation - local
Chemo - distant
Hormone therapy - advanced stage, well-differnetiated (grade 1)
Followup of endometrial cancer
For recurrence:
- Pelvic exam q6/12 for 2-3 y, then annually
- Screening tests are NOT USEFUL
- most are symptomatic (vaginal bleeding)
- majority recur in pelvis
To maximize survivorship:
- reduces risk of other cancers
- QOL
Type I endometrial ca
“low risk”
more common
Age ~62 (20%
Type I endometrial ca risk factors
Estrogen-related (E>P)
obesity: conversion of androstenediol –> estrogen
PCOS
T2DM: hyperinsulinemia
Tamoxifen: selective estrogen receptor modulator - used to treat breast ca, but increases endometrial hyperplasia
Type II endometrial ca
high risk
rare
age ~70
almost always postmenopausal
NOT estrogen related, more likely to have normal BMI
non-endometriod: serous, clear cell, malignant mixed mullerian tumour (carcinosarcoma)
All high grade (grade 3)